BUSINESS
Emcure launches knock-off of Eisai's cancer drug Halaven at 40% lower price in India
Emcure is confident of overcoming any patent challenge by the innovator, as it claims its version is developed through a non-infringing process.
BUSINESS
Sudarshan Jain, former Abbott top executive, is IPA Secretary General
The appointment of Jain follows the demise of DG Shah in February.
BUSINESS
Cipla's HR head Prabhir Jha quits, floats advisory firm
Jha on his Linkedin announced that he will be starting a new journey launching advisory venture called Prabir Jha People Advisory, where he will be helping companies on people's practices
BUSINESS
Cardiac stents price to rise by 8% YoY
Drug eluting stents or the stents coated with a drug, constitutes 95 percent of the market
HEALTH-TRENDS
How our political discourse stigmatises mental health
Stigmatization of mental illness, becomes a major barrier for people with mental health problems to seek professional help, as they fear being labelled and bullied.
BUSINESS
Delhi police files criminal case against Singh brothers for causing Rs 2,397 crore loss to Religare
Earlier this month stock market regulator the Securities and Exchange Board of India (SEBI) has directed Religare Enterprises and Religare Finvest to recover loans worth Rs 2,315.09 crore from the Singh brothers and entities related to them.
BUSINESS
Adani Group may join race to acquire GMR's Kakinada SEZ and port
GMR owns 51 percent in Kakinada SEZ Ltd which is developing a multi-product SEZ spanning over 10,000 acres, near Kakinada, in addition to having a license to build a multipurpose all weather deep draft port, as part of SEZ at an investment of Rs 2,123 crore.
BUSINESS
New clinical trial rules to boost growth of clinical research industry
The New Drugs and Clinical Trial Rules state the any drug discovered in India and proposed to be manufactured and marketed in India, will be deemed approval for clinical trials in 30 working days, if no communication received from the Central Licensing Authority (CLA).
BUSINESS
GMR to spin-off airports business, eyes profitability in FY20
GMR on March 27 said it has signed a binding term sheet with a consortium of a Tata Group company, Singapore's sovereign wealth fund GIC and SSG Capital Management for raising Rs 8,000 crore in its airports business.
BUSINESS
Venture Catalysts to invest $10-15 million in early stage health startups
Venture Catalysts announced tie-up with UK-based health-focused innovation platform Well Tech to launch first ever accelerator programme for Indian startups focussing on healthcare.
BUSINESS
Netmeds buys health tech start-up KiViHealth for $10 million
The acquisition helps Netmeds to transform into a complete healthcare product and service company.
BUSINESS
Weekly wrap: A series of OAIs highlights Indian pharma's choppy ride in 2019
All these come at a time when Indian drug makers last year have shown considerable improvement in inspection outcomes and have reached in line with the global trend
BUSINESS
Apollo bets on apartments and housing societies to expand primary care clinics
Apollo plans to add 10-15 clinics every year going forward, and has also tied-up with ApnaComplex, a company that manages apartment complexes, gated communities and co-operative housing societies to setup Society Clinics.
BUSINESS
Time may be running out for Singh brothers to pay up, even as the blame game continues
Not long ago, Singh brothers were on the Forbes richest Indian businessmen list, with a net worth of $1.4 billion in 2016
BUSINESS
SEBI directs Singh brothers to pay Rs 403 crore to Fortis Health within 3 months
The regulator also ordered Singh brothers or their companies not dispose of or alienate any of their assets or divert any funds pending completion of the investigation and till further orders.
BUSINESS
Abbott takes digital route in India to improve patient health outcomes
“It’s a neutral platform, designed to bridge the communication gap between doctors and consumers,” said Jawed Zia, Head of Abbott’s Pharmaceutical Business in India.
BUSINESS
Lupin's USFDA regulatory compliance woes may not augur well for US business revival
While an OAI classification doesn’t impact existing supplies and revenues from operations of this facility, but blocks new product approvals filed from the site. In addition it may even trigger a warning letter or import ban, if fails to satisfactorily address the concerns raised by USFDA.
BUSINESS
Pharma wrap: India's predicament of controlling patented anti-cancer medicine prices
The spiralling costs of patented cancer drugs has come to focus with governments in the developed and developing world grappling to deal with the problem.
BUSINESS
Pharma packaging firm Schott Kaisha rides on Indian drug companies' injectables push
The company which has two plants in Daman and Jambusar near Vadodara, and plans to add new manufacturing facilities in Daman and Baddi.
BUSINESS
Sun Pharma auditor files case against Macquarie with Economic Offences Wing: Sources
Macquarie, an Australian multinational independent investment bank and financial services company, questioned corporate governance practices at Sun Pharma, causing the drugmaker's shares to end at a six-month low on November 29, 2018.
BUSINESS
Govt trade margin cap falls short of curbing prices of most cancer drugs, but highlights trade distortion
The government said this is just a pilot, indicating that it may extend trade margin rationalization to other drugs as well.
BUSINESS
Piramal's contract manufacturing arm eyes US generics business via partner-led model
“We are a solution partner. We leverage our contract development and manufacturing (CDMO) capabilities, we work on the R&D and manufacturing of the product, and the partner takes care of distribution,” Vivek Sharma CEO of Piramal Pharma Solutions.
BUSINESS
Everstone Group picks stake in Chennai-based medical devices maker CPC Diagnostics
With this strategic investment, Everlife plans to support CPC’s manufacturing and distribution capabilities within India and South-East Asia, to become the leading IVD distributor in the region.
BUSINESS
L&T poised to meet FY19 order inflow guidance on pre-election boost
L&T needs around Rs 42,000 crore in the fourth quarter to meet the FY19 guidance.
